PL3019482T3 - Trójpodstawione pochodne benzotriazolu jako inhibitory oksygenazy dihydroorotanu - Google Patents

Trójpodstawione pochodne benzotriazolu jako inhibitory oksygenazy dihydroorotanu

Info

Publication number
PL3019482T3
PL3019482T3 PL14754772T PL14754772T PL3019482T3 PL 3019482 T3 PL3019482 T3 PL 3019482T3 PL 14754772 T PL14754772 T PL 14754772T PL 14754772 T PL14754772 T PL 14754772T PL 3019482 T3 PL3019482 T3 PL 3019482T3
Authority
PL
Poland
Prior art keywords
benzotriazole derivatives
oxygenase inhibitors
trisubstituted benzotriazole
dihydroorotate oxygenase
dihydroorotate
Prior art date
Application number
PL14754772T
Other languages
English (en)
Inventor
Siva Sanjeeva Rao Thunuguntla
Subramanya Hosahalli
Satish Reddy Kunnam
Original Assignee
Aurigene Discovery Technologies Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Technologies Limited filed Critical Aurigene Discovery Technologies Limited
Publication of PL3019482T3 publication Critical patent/PL3019482T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL14754772T 2013-02-25 2014-02-24 Trójpodstawione pochodne benzotriazolu jako inhibitory oksygenazy dihydroorotanu PL3019482T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN825CH2013 2013-02-25
EP14754772.3A EP3019482B1 (en) 2013-02-25 2014-02-24 Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
PCT/IB2014/059204 WO2014128669A2 (en) 2013-02-25 2014-02-24 Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors

Publications (1)

Publication Number Publication Date
PL3019482T3 true PL3019482T3 (pl) 2019-02-28

Family

ID=51391932

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14754772T PL3019482T3 (pl) 2013-02-25 2014-02-24 Trójpodstawione pochodne benzotriazolu jako inhibitory oksygenazy dihydroorotanu

Country Status (14)

Country Link
US (4) US9630932B2 (pl)
EP (2) EP3019482B1 (pl)
CY (1) CY1120826T1 (pl)
DK (1) DK3019482T3 (pl)
ES (1) ES2694829T3 (pl)
HR (1) HRP20181908T1 (pl)
HU (1) HUE042032T2 (pl)
LT (1) LT3019482T (pl)
PL (1) PL3019482T3 (pl)
PT (1) PT3019482T (pl)
RS (1) RS57962B1 (pl)
SI (1) SI3019482T1 (pl)
SM (1) SMT201800580T1 (pl)
WO (1) WO2014128669A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2694829T3 (es) 2013-02-25 2018-12-27 Aurigene Discovery Technologies Limited Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa
US20190192501A1 (en) * 2016-08-23 2019-06-27 Icahn School Of Medicine At Mount Sinai Methods for treating pten-mutant tumors
US10968216B2 (en) 2016-10-27 2021-04-06 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
MA47593A (fr) * 2017-02-24 2020-01-01 Merck Patent Gmbh Dérivés de 1, 4, 6-trisubstitué-2-alkyl-1h-benzo[d]imidazole en tant qu'inhibiteurs de dihydroorotate oxygénase
CA3060390A1 (en) * 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
CA3103557A1 (en) 2018-06-22 2019-12-26 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase
AU2019351124A1 (en) 2018-09-28 2021-05-20 Acucela Inc. Inhibitors of VAP-1
EP3856176A4 (en) 2018-09-28 2022-05-04 Acucela Inc. INHIBITORS OF VAP-1
BR112021012305A2 (pt) * 2018-12-21 2021-10-05 Les Laboratoires Servier Sas Formas cristalinas e salinas de um composto orgânico e composições farmacêuticas das mesmas
US20230285364A1 (en) 2020-06-24 2023-09-14 Servier Pharmaceuticals Llc Use of a dhodh inhibitor compound in combination cancer therapy
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
KR20230078997A (ko) 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도
WO2022167402A1 (en) 2021-02-02 2022-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of therapy comprising administering a therapeutically effective combination comprising a dhodh inhibitor and an idh inhibitor
WO2023280181A1 (zh) * 2021-07-05 2023-01-12 微境生物医药科技(上海)有限公司 用作dhodh抑制剂的1,2,4-三唑酮衍生物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU649421B2 (en) 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
US5904937A (en) 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
DE102005049953A1 (de) * 2005-10-19 2007-04-26 Sanofi-Aventis Deutschland Gmbh Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
KR101177729B1 (ko) * 2006-09-08 2012-09-07 에프. 호프만-라 로슈 아게 벤조트리아졸 키나아제 조절제
WO2010081898A1 (en) * 2009-01-19 2010-07-22 Neurosearch A/S Novel benzotriazole derivatives useful for the treatment of cns disorders
SG174125A1 (en) * 2009-04-02 2011-10-28 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
ES2694829T3 (es) 2013-02-25 2018-12-27 Aurigene Discovery Technologies Limited Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa

Also Published As

Publication number Publication date
SI3019482T1 (sl) 2018-12-31
US9937155B2 (en) 2018-04-10
ES2694829T3 (es) 2018-12-27
HUE042032T2 (hu) 2019-06-28
US10080740B2 (en) 2018-09-25
US20190105304A1 (en) 2019-04-11
RS57962B1 (sr) 2019-01-31
EP3019482A2 (en) 2016-05-18
LT3019482T (lt) 2018-11-26
EP3019482A4 (en) 2017-05-10
WO2014128669A2 (en) 2014-08-28
HRP20181908T1 (hr) 2019-01-11
US20180021311A1 (en) 2018-01-25
US20160200693A1 (en) 2016-07-14
US20170224663A1 (en) 2017-08-10
PT3019482T (pt) 2018-11-28
US9630932B2 (en) 2017-04-25
EP3417850A1 (en) 2018-12-26
DK3019482T3 (en) 2018-11-12
SMT201800580T1 (it) 2019-01-11
EP3019482B1 (en) 2018-08-15
CY1120826T1 (el) 2019-12-11
WO2014128669A3 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
SI3019482T1 (sl) Derivati trisubstituiranega benzotriazola kot inhibitorji dihidroorotat oksigenaze
ZA201800913B (en) Syk inhibitors
IL243578A0 (en) syk inhibitors
HUE043398T2 (hu) Glikozidáz inhibítorok
EP2948450A4 (en) METALLOENZYMINHIBITORVERBINDUNGEN
EP2970340A4 (en) BETA-Lactamase INHIBITORS
EP2943204A4 (en) BETA-Lactamase INHIBITORS
IL240962A0 (en) cdc7 inhibitors
IL240805B (en) Naphthyridine and quinoline compounds as mao inhibitors
EP3049435A4 (en) Factor xia inhibitors
ZA201506156B (en) Novel inhibitors
EP3054944A4 (en) FACTOR XIa INHIBITORS
EP2885291A4 (en) INHIBITORS OF VEGFR3
ZA201508968B (en) Imidazo-triazine derivatives as pde10 inhibitors
EP2885292A4 (en) VEGFR3 INHIBITORS
EP3010913A4 (en) Piperidinolbenzimidazole derivatives as MPGE-1 inhibitors